Larimar Therapeutics Inc. (LRMR): JMP Securities sees 500% price potential, and LifeSci Capital even declared a tenbagger potential!
Reading Time: 4 minutes
Larimar Therapeutics Inc. (LRMR) (i.) specializes in the development of treatments for patients with complex, rare diseases utilizing its novel platform for cell-penetrating peptides. The company focuses particularly on diseases resulting from mitochondrial dysfunctions, such as Friedreich's Ataxia (FA). With Nomlabofusp (CTI-1601), the firm has a product in the pipeline that is a recombinant fusion protein designed to transport human frataxin (FXN) – an essential protein – into the mitochondria of patients with FA. FA is a rare, progressive,...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
